Silexion doses first patient in SIL204 pancreatic cancer trial
Silexion said the first patient has been dosed in its Phase 2/3 SIL204 trial for locally advanced pancreatic cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Silexion Therapeutics doses first patient in Phase 2/3 SIL204 pancreatic cancer trial
Global trial is testing SIL204 with standard chemotherapy versus chemotherapy alone in newly diagnosed KRAS-mutated, unresectable stage 3 patients. First dosing occurred at Tel Aviv Sourasky Medical Center, with additional sites in Israel and Germany moving toward activation.
Silexion Therapeutics Corp. (SLXN) Doses First Patient in Phase 2/3 SIL204 Trial
Silexion Therapeutics Corp. dosed the first patient in its multinational Phase 2/3 trial of SIL204 plus chemotherapy in locally advanced pancreatic cancer, starting at Tel Aviv Sourasky Medical Center, with expansion sites planned in Israel and Germany.Material DetailsContext by AI AnalystThis is a…
Silexion Therapeutics doses first patient in Phase 2/3 trial
Silexion Therapeutics said the first patient was successfully dosed in its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.